| Message: | Product Name CJC-1295 Acetate
Sequence Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-Lys(Maleimidopropionyl)-NH2
Cas No. 863288-34-0
Molecular Formula C165H271N47O46
Molecular Weight 3649.30
Purity (HPLC) 98.0%
Appearance? White powder
Single Impurity(HPLC)? 1.0%
Amino Acid Composition? 10% of theoretical
Peptide Content(N%) 80%(by %N)
Water Content(Karl Fischer)? 6.0%
Acetate Content(HPIC) 15.0%
MS(ESI)
Mass Balance? 95.0～105.0%
2. Description:
CJC-1295 is a derivative of human GH-releasing factor1-29(HGRF1-29). HGRF1-29 is a naturally occurring peptide that is actually a truncated form of a larger peptide that binds to the growth hormone secretagogue receptor (GHS-R) and causes the release of growth hormone. CJC-1295 has four amino acids substituted in its chain that result in strong binding to serum albumin and prolong its half-life in the body.
Because of the way CJC-1295 is engineered its half life has been extended from ~7 minutes to greater than 7 days!. This is convenient as it means the product only needs to be injected 1-2 times per week for continuously elevated levels of Human Growth Hormone (HGH) and IGF-1. A single subcutaneous (sc) injection results in measurable quantities of CJC-1295 in the blood for up to 13 days. Additionally, a single dose of 60 ug/kg of CJC-1295 results in elevated levels of growth hormone (125%) while the pulsatile secretion of GH is maintained. Furthermore, 60 ug/kg of CJC-1295 elevated IGF-1 levels to the upper limit of normal. A dose of 30 ug/kg of CJC-1295 given weekly maintained its response with no evidence of desensitization.
|
my account
